Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 6/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | CIT | O14578 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CTSH | P09668 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210345 | 0.90 | CTSC (0.43) | CTSCDPP4CYP1A2CYP3A4CTSH | |
| SCHEMBL7136092 | 0.84 | DPP4 (0.49) | DPP4 | |
| SCHEMBL9221199 | 0.81 | CTSC (0.43) | CTSCDPP4CTSHCTSK | |
| SCHEMBL25530472 | 0.77 | DPP4 (0.36) | DPP4ROCK2CITCYP3A4AAK1 | |
| SCHEMBL4046388 | 0.77 | KDM4E (0.32) | — | |
| SCHEMBL14404899 | 0.73 | DPP4 (0.33) | DPP4ROCK2CITAAK1 | |
| SCHEMBL5191383 | 0.73 | GRN (0.46) | DPP4ROCK2 | |
| SCHEMBL14167270 | 0.72 | DPP4 (0.41) | DPP4ROCK2CITAAK1 | |
| SCHEMBL12883235 | 0.72 | DPP4 (0.41) | DPP4ROCK2CITAAK1 | |
| SCHEMBL24832183 | 0.71 | SCN9A (0.41) | DPP4ROCK2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | CTSC 619/4885DPP4 552/4885ROCK2 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.